News

Galapagos NV and AbbVie recently expanded their collaborative agreement in cystic fibrosis (CF) to mirror the successful growth of their CF portfolio, with an ultimate goal of developing a triple combination therapy able to treat 90 percent of all cystic fibrosis patients. Triple combinations of CF compounds already in the companies’…

Concert Pharmaceuticals, Inc., which is developing new small molecule drugs through its DCE (deuterated chemical entity) Platform, recently announced positive results from a Phase 1 clinical trial of its cystic fibrosis (CF) treatment, CTP-656 (deuterium-modified ivacaftor). The data, which included a positive safety and tolerability profile, support the continuing development of CTP-656 as…

Pulmonary exacerbations have a negative impact on the general health-related quality of life in people with cystic fibrosis (CF), a study reported, stressing the importance of preventing such flares in this group. Assessing general, as opposed to disease-specific, health-related quality of life measures are needed when comparing different disease conditions and determining the usefulness of…

ACT.md recently reported positive preliminary results from a multiyear project — in partnership with Boston Medical Center and Baystate Health — using the company’s “Collaborative Consultative Care Coordination Program” (4C) to measure improvements in quality of life, family engagement, and healthcare costs for children affected by medically complex conditions like cystic fibrosis. First results…